Abstract
Individuals experiencing recurrent malaria infections encounter a variety of alleles with each new infection. This ongoing allelic diversity influences the development of naturally acquired immunity and it can inform vaccine efficacy. To investigate the diversity and infection variability, Plasmodium falciparum merozoite surface protein 1 (Pfmsp1), a crucial protein for parasite invasion and immune response, was assessed in parasites isolated from children with repeated malaria episodes. A total of eleven microhaplotypes were observed across all malaria episodes. There were 4 prevalent microhaplotypes, E-KSNG-L, Q-KSNG-L, Q-KSNG-F, and Q-KNNG-L, in the population. Conversely, microhaplotypes such as E-KSSR-L, E-KNNG-L, E-KSSG-L, E-TSSR-L (3D7), Q-TSSR-L, E-TSSG-L, and E-KSNG-F were rare and maintained at low frequencies. High allelic replacements were observed, however some individuals experienced consecutive re-infections with the same microhaplotype. Notably, Pfmsp119 allelic diversity as measured by haplotype diversity was stable, while nucleotide diversity decreased over time with decreasing parasitemia. Parasite Pfmsp119 allelic diversity remained stable over the multiple malaria episodes, despite declining parasitaemia levels and ongoing immune development. In addition, our findings reveal dynamic Pfmsp119 allelic replacements across parasite infection episodes, with initial immune responses to prevalent variants potentially waning over time, allowing for re-infections. Overall, our findings emphasize that protective immunity to malaria involves complex immune responses targeting multiple alleles that wane over time and thus the development of sterilizing immunity is a challenge.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work was supported by the malaria capacity development consortium (MCDC) re-entry grant and a Wellcome Trust Intermediate Fellowship (107568/Z/15/Z) to LIO-O, who is currently supported by a Calestous Juma fellowship from BMGF INV036442. RMY was supported by a University of Nairobi (UoN) scholarship administered through the Centre for Biotechnology and Bioinformatics (CEBIB). We extend our gratitude to UoN and CEBIB.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Scientific Ethics Review Unit (SERU) institutional ethical review (SERU 3149. Sampling done from 2008-2013
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes